Drugs / Ritonavir
Ritonavir
also known as
RTV · Norvir · ritonavir also known as norvir · ABT-538 · Norvir (ritonavir) · A-84538 · ABBOTT-84538 · Empetus · +16 more
Other / unclassified targets CYP2B6, CYP3A4 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed COVID-19 1 milestone | |||||
| Filed | US (FDA) | PAXLOVID | COVID-19 | 2022-06-30 | “submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets)” pfizer.com ↗ |
| Approved Indication not stated 3 milestones | |||||
| Label expansions (3) | US (FDA) | NORVIR | — | 1997-03-14 – 2005-10-06 | fda.gov ↗ |
| Approved | EU (EMA) | Norvir | — | 1996-08-25 | europa.eu ↗ |
| Approved | US (FDA) | NORVIR | — | 1996-03-01 | fda.gov ↗ |
Trials 461 · started per year
today
US approved 1996
EU approved 1996
1
2
10
12
14
17
17
11
21
22
31
23
25
25
21
17
14
24
21
18
8
7
5
24
8
23
12
2
4
1
199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
News releases announcing trial results or a regulatory action · 98
| Date | Issuer | Release |
|---|---|---|
| 2025-11-05 | Shionogi | Results New Clinical Data on the Efficacy of Antiviral Treatments for Post-COVID-19 Condition shionogi.com ↗
The incidence of PCC was approximately 26% in the non-antiviral group (N=5,518) and approximately 24% in the antiviral group (N=2,181, combined group of ensitrelvir, nirmatrelvir/ritonavir, and molnupiravir). |
| 2024-07-23 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Regulatory Fully Approved! XIANNUOXIN® Becomes the First Oral Anti-COVID-19 Drug Obtaining Regular Approval in China simcere.com ↗
XIANNUOXIN ® has become the first oral anti-COVID-19 drug obtaining regular approval in China. |
| 2023-07-14 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Results Study of XIANNUOXIN® Aiming to Validate the Efficacy and Safety of SIM0417 plus Ritonavir Published in The Lancet simcere.com ↗ |
| 2023-05-25 | Pfizer | Regulatory Pfizer’s PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19 pfizer.com ↗ |
| 2023-03-16 | Pfizer | Regulatory FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™ pfizer.com ↗
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted 16 to 1 that available data support the safety and effectiveness of PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 in adult patients who are at high risk for progression to severe illness. |
| 2023-01-29 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Regulatory XIANNUOXIN® - The First Chinese 3CL Anti-COVID-19 Drug - Receives Approval from the NMPA simcere.com ↗
XIANNUOXIN is approved for adults suffering from "mild to moderate COVID-19." |
| 2023-01-16 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Regulatory Innovative, Potential Best-in-Class, Anti-COVID-19 Drug, XIANNUOXIN® has Received an Accepted New Drug Application from the NMPA simcere.com ↗
has been accepted by the National Medical Products Administration (NMPA) and will be reviewed in special drug approval procedures. |
| 2022-12-29 | Shanghai Junshi Bioscience Co., Ltd. | Results 君实生物宣布《新英格兰医学杂志》发表口服抗新冠病毒药物VV116对比PAXLOVID治疗伴有高风险因素的轻/中度COVID-19患者III期临床研究结果 junshipharma.com ↗
在FAS人群中，VV116与PAXLOVID在“至持续临床恢复的时间”达到非劣效（HR=1.17，95%CI：1.02~1.36），且VV116组比PAXLOVID组的中位恢复时间更短（4天 vs. 5天）。 |
| 2022-06-30 | Pfizer | Regulatory Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™ pfizer.com ↗
The submission provides the longer-term follow-up data necessary for acceptance and potential approval. |
| 2022-06-14 | Pfizer | Results Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA pfizer.com ↗
Pre-specified secondary endpoint resulted in a nominally significant 62% decrease in COVID-19-related medical visits per day across all patients, relative to placebo |
| 2022-06-14 | Drugs for Neglected Diseases | Regulatory Cipla and DNDi launch child-friendly 4-in-1 antiretroviral treatment for young children living with HIV in South Africa dndi.org ↗
The South African Health Products Regulatory Authority (SAHPRA) has approved a sweet-tasting, heat-stable, ‘4-in-1’ fixed-dose combination of four antiretroviral (ARV) treatments composed of abacavir, lamivudine, lopinavir, and ritonavir that is specifically designed for infants and young children with HIV. |
| 2022-01-27 | Pfizer | Regulatory Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment pfizer.com ↗
CHMP recommends PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for use in adults with COVID-19 |
| 2021-12-22 | Pfizer | Regulatory Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment pfizer.com ↗
PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) is authorized for emergency use in both high-risk adults and high-risk pediatric patients 12 years of age and older weighing at least 40 kg |
| 2021-12-16 | Pfizer | Regulatory EMA Issues Advice for Potential Early Use of Pfizer’s Novel COVID-19 Oral Antiviral Candidate pfizer.com ↗
The CHMP also recommend that PAXLOVID should be administered as soon as possible after diagnosis of COVID-19 and within five days of the start of symptoms. |
| 2021-12-14 | Pfizer | Results Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death pfizer.com ↗ |
| 2021-11-16 | Pfizer | Regulatory Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate pfizer.com ↗
Pfizer Inc. today announced it is seeking Emergency Use Authorization (EUA) of its investigational oral antiviral candidate, PAXLOVID™ (PF-07321332; ritonavir), for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalizations or death. |
| 2021-11-05 | Pfizer | Results Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study pfizer.com ↗
PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adults with COVID-19 |
| 2019-10-21 | Ascletis Pharmaceuticals Co., Ltd. | Results Manuscript Publication of the First All-oral DAA HCV Regimen Developed by Ascletis from China in the Journal of Clinical and Translational Hepatology ascletis.com ↗
The RDV/DNVr regimen was with good safety and tolerability. |
| 2018-11-06 | Ascletis Pharmaceuticals Co., Ltd. | Results Ascletis to Present Phase II / III Clinical Study for Its Innovative All-oral HCV Treatment at the 69th Annual meeting of AASLD ascletis.com ↗
The results show that RDV/DNV Regimen demonstrated a cure rate of 99% (SVR12) with a short treatment duration of 12 weeks in treatment-naïve non-cirrhotic HCV genotype 1 Chinese patients. |
| 2018-07-24 | Merck Sharp & Dohme LLC | Results Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine merck.com ↗
73.1 percent (277/379) of the group treated with once-daily DOR achieved viral suppression |
| 2017-10-04 | Gilead Sciences | Results Gilead Presents Results From Phase 3 Study Evaluating Patients Who Switched to Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide From Boosted Protease Inhibitor-Based Regimens gilead.com ↗
In the ongoing study, BIC/FTC/TAF was found to be statistically non-inferior to regimens containing bPIs and demonstrated no treatment-emergent resistance at 48 weeks. |
| 2017-07-25 | GlaxoSmithKline | Results ViiV Healthcare announces superior efficacy of dolutegravir versus lopinavir/ritonavir in second-line HIV treatment in resource-limited settings gsk.com ↗
The 24-week interim data showed an 82% response rate in the dolutegravir arm versus 69% for lopinavir/ritonavir (p<0.001). |
| 2017-06-05 | Drugs for Neglected Diseases | Regulatory Child-friendly formulation of WHO-recommended HIV treatment now approved by the CDSCO | DNDi dndi.org ↗
On 25 May, an expert committee of the Central Drugs Standard Control Organization (CDSCO), the Indian drug regulatory authority, finally permitted the child-friendly and heat-stable pellet formulation of the HIV drug lopinavir/ritonavir (LPV/r) to be registered. |
| 2017-02-27 | AbbVie | Regulatory AbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic Hepatitis C abbvie.com ↗
With this positive CHMP opinion, we will bring an eight-week treatment option for the many HCV patients with GT1b. |
| 2017-02-14 | Merck Sharp & Dohme LLC | Results Merck’s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection, Met Primary Efficacy Endpoint in Pivotal Phase 3 Trial merck.com ↗
In addition, a secondary endpoint showed that the DOR-treated group had statistically significant lower levels of fasting low density lipoprotein cholesterol (LDL-C), versus the DRV+r group. |
| 2017-02-13 | Drugs for Neglected Diseases | Results Study confirms key therapeutic advance for children living with HIV and tuberculosis | DNDi dndi.org ↗
The study, presented as a late-breaker this week at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, provides essential evidence and data to counter the negative interactions between two critical HIV and TB treatments. |
| 2017-01-09 | AbbVie | Results Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) for Chronic Hepatitis C Achieved High SVR[12] Rates in Genotype 1 Japanese Patients abbvie.com ↗
In top-line results from the Phase 3 CERTAIN-1 study, 99 percent (n=105/106) of patients without cirrhosis, which represents the majority of HCV patients, and without the Y93H variant achieved sustained virologic response at 12 weeks post treatment (SVR 12 ). |
| 2016-09-23 | AbbVie | Results AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C abbvie.com ↗
In the Phase 3b GARNET study, 98 percent (n=160/163) of previously untreated patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection without cirrhosis achieved sustained virologic response rates at 12 weeks post-treatment (SVR 12 ). |
| 2016-07-25 | AbbVie | Regulatory CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A) abbvie.com ↗ |
| 2016-07-25 | AbbVie | Regulatory AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C abbvie.com ↗
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir) extended-release tablets. |
| 2016-07-25 | Enanta Pharmaceuticals, Inc | Regulatory Enanta Announces the U.S. Food and Drug Administration has approved AbbVie’s New, Once-Daily VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C Virus enanta.com ↗ |
| 2016-07-18 | GlaxoSmithKline | Results ARIA study shows superior efficacy of Triumeq® for treatment-naïve women living with HIV gsk.com ↗
ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study which showed superior efficacy for Triumeq® (dolutegravir/abacavir/lamivudine) compared with atazanavir boosted with ritonavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in 495 treatment-naïve women living with HIV. |
| 2016-04-25 | Enanta Pharmaceuticals, Inc | Regulatory Enanta Announces U.S. FDA has Approved AbbVie’s Supplemental New Drug Application for Use of VIEKIRA PAK® without Ribavirin in Genotype 1b Chronic Hepatitis C Patients with Compensated Cirrhosis enanta.com ↗ |
| 2016-04-15 | AbbVie | Results AbbVie Announces Real-World Data with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) from Large German Hepatitis C-Registry abbvie.com ↗
These data support results seen in Phase 3 clinical trials for chronic GT1 or GT4 hepatitis C virus (HCV) infected patients treated with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) with or without ribavirin (RBV). |
| 2016-04-14 | AbbVie | Results AbbVie Announces High SVR Rates with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) Regardless of the Presence of Resistance-Associated Variants Prior to Treatment in Genotype 1 Chronic Hepatitis C Patients abbvie.com ↗ |
| 2016-03-30 | AbbVie | Results AbbVie to Present Data on VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) and Investigational, Pan-Genotypic Regimen at The International Liver Congress™ 2016 abbvie.com ↗
Ombitasvir/Paritaprevir/Ritonavir With Ribavirin Achieves High Sustained Virologic Response (SVR) Rates in Egyptian Adults With Chronic HCV Genotype 4 Infection (AGATE-II) |
| 2016-02-26 | AbbVie | Regulatory AbbVie Receives CHMP Positive Opinion for VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) Without Ribavirin for the Treatment of Chronic Hepatitis C in Genotype 1b Patients with Compensated Cirrhosis (Child-Pugh A) in abbvie.com ↗ |
| 2016-02-26 | Enanta Pharmaceuticals, Inc | Regulatory Enanta Pharmaceuticals Announces CHMP Positive Opinion for AbbVie’s VIEKIRAX® + EXVIERA® Without Ribavirin for the Treatment of Chronic Hepatitis C in Genotype 1b Patients with Compensated Cirrhosis enanta.com ↗
the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion |
| 2016-01-07 | AbbVie | Regulatory FDA Grants Priority Review to AbbVie for Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chronic Hepatitis C Virus Patients with Compensated Cirrhosis abbvie.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) and granted priority review for VIEKIRA PAK |
| 2016-01-07 | Enanta Pharmaceuticals, Inc | Regulatory Enanta Pharmaceuticals Announces the U.S. FDA Grants Priority Review to AbbVie’s Supplemental New Drug Application for VIEKIRA PAK® Without Ribavirin in Genotype 1B Chronic Hepatitis C Virus Patients with Compensated Cirrhosis enanta.com ↗ |
| 2015-12-02 | AbbVie | Regulatory AbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily Formulation of VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) to Treat Genotype 1 Chronic Hepatitis C Virus Infection abbvie.com ↗ |
| 2015-12-02 | Enanta Pharmaceuticals, Inc | Regulatory Enanta Pharmaceuticals Announces FDA Acceptance of AbbVie’s New Drug Application for a Once-Daily Formulation of VIEKIRA PAK® for the Treatment of Genotype 1 Chronic Hepatitis C Virus Infection enanta.com ↗
today announced AbbVie’s New Drug Application (NDA) has been accepted by the U.S. Food and Drug Administration (FDA) for a once-daily, fixed-dose formulation of the components of VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets). |
| 2015-11-14 | AbbVie | Results AbbVie Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Patients with Chronic Hepatitis C Virus Infection With or Without Compensated Cirrhosis abbvie.com ↗
Results show that 95 percent (n=586/615) of patients in the TOPAZ-II trial achieved a sustained virologic response at 12 weeks post-treatment (SVR 12 ) after 12 or 24 weeks of treatment, a secondary endpoint for the study. |
| 2015-11-14 | Enanta Pharmaceuticals, Inc | Results Enanta Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Patients with Chronic Hepatitis C Virus Infection With or Without Compensated Cirrhosis enanta.com ↗
Interim data show that 95 percent (n=586/615) of patients in the TOPAZ-II trial achieved a sustained virological response at 12 weeks post-treatment after 12 or 24 weeks of treatment, a secondary endpoint for the study. |
| 2015-10-22 | AbbVie | Regulatory AbbVie Updates U.S. Labels for VIEKIRA PAK® and TECHNIVIE™ abbvie.com ↗
The USPIs for VIEKIRA PAK and TECHNIVIE were updated following post-marketing reports of hepatic decompensation and hepatic failure, including liver transplantation or fatal outcomes, in patients receiving AbbVie’s HCV treatment, with or without RBV. |
| 2015-09-28 | AbbVie | Regulatory AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) Receives Approval in Japan for the Treatment of Genotype 1 Chronic Hepatitis C abbvie.com ↗ |
| 2015-09-11 | AbbVie | Results Ongoing Real World Study Reports High Sustained Viral Response Rates with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Genotype 1 Hepatitis C Patients abbvie.com ↗
This study of Polish patients who reached post-treatment at week 12 (n=40 of 186 enrolled to date), demonstrated 98 percent (n=39/40) SVR 12 . |
| 2015-07-24 | AbbVie | Regulatory TECHNIVIE™ (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA Approval as the First and Only All-Oral, Interferon-Free Treatment for Genotype 4 Chronic Hepatitis C in the U.S. abbvie.com ↗
TECHNIVIE is the first and only all-oral, interferon-free, direct-acting antiviral treatment approved in the U.S. for adult patients with GT4 chronic HCV infection. |
| 2015-07-24 | Enanta Pharmaceuticals, Inc | Regulatory Enanta Pharmaceuticals Announces U.S. Regulatory Approval of TECHNIVIE™ (ombitasvir, paritaprevir and ritonavir) tablets enanta.com ↗ |
| 2015-07-21 | Bristol-Myers Squibb | Results Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continued Development bms.com ↗
In addition, a lower dose of BMS-955176 (40 mg) plus atazanavir and ritonavir had a similar maximum median change in HIV-1 RNA of -2.20 log 10 c/mL. |
| 2015-06-24 | AbbVie | Results AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis abbvie.com ↗
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained virologic response at 12 weeks post-treatment (SVR 12 ) in genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected adult patients with compensated liver cirrhosis. |
| 2015-06-02 | Drugs for Neglected Diseases | Regulatory Child-friendly formulation of WHO-recommended treatment now approved by the US FDA for children living with HIV | DNDi dndi.org ↗
Infants and young children living with HIV will finally have access to an improved formulation of an antiretroviral (ARV) treatment, following the U.S. Food and Drug Administration’s (FDA) tentative approval last week of lopinavir/ritonavir (LPV/r) oral pellets developed by the Indian generic company Cipla. |
| 2015-05-26 | AbbVie | Results AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis abbvie.com ↗
The primary endpoint was achieved, demonstrating 95 percent (n=106/112) SVR 12 in a sub-group of treatment-naïve, non-cirrhotic, adult GT1b HCV infected Japanese patients who were eligible for therapy with IFN and had a high viral load. |
| 2015-04-25 | AbbVie | Results AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® + EXVIERA® in Chronic Hepatitis C Patients with Renal Impairment at The International Liver Congress™ 2015 abbvie.com ↗
Patients who reached post-treatment week four to date (n=10 of 20 enrolled) achieved 100 percent SVR 4 (n=10/10). |
| 2015-04-24 | AbbVie | Regulatory U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C abbvie.com ↗
AbbVie (NYSE: ABBV) has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV). |
| 2015-04-15 | AbbVie | Regulatory AbbVie's Investigational Chronic Hepatitis C Treatment Granted Priority Review in Japan abbvie.com ↗
AbbVie (NYSE: ABBV) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted priority review for its investigational, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir. |
| 2015-04-13 | Ascletis Pharmaceuticals Co., Ltd. | Results HCV RACE IN CHINA ascletis.com ↗
In 30 non-cirrhotic patients with genotype 1b infection, 97% achieved an SVR12. |
| 2015-04-08 | AbbVie | Results AbbVie to Present New Data from Hepatitis C Clinical Development Program at The International Liver Congress™ 2015 abbvie.com ↗
No Significant Interaction Among Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir and Sofosbuvir |
| 2015-02-23 | AbbVie | Results Results from AbbVie's Study of VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) Published Online in JAMA; Sub-analyses to be Presented at the Annual Confere abbvie.com ↗
The SVR 12 rates were 91 percent (n=51/56) for subjects with HCV GT1a infection and 100 percent (n=7/7) for those with HCV GT1b infection. |
| 2015-02-11 | AbbVie | Regulatory AbbVie Submits New Drug Application in Japan for its Investigational, All-Oral, Treatment for Chronic Hepatitis C abbvie.com ↗
AbbVie (NYSE: ABBV) submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval for the company's investigational, all-oral, ribavirin (RBV) and interferon (IFN)-free, 12-week, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r), dosed once daily. |
| 2015-01-30 | AbbVie | Results AbbVie Announces Top-line Results from Phase 3 Study of All-Oral Treatment for Hepatitis C in Japan abbvie.com ↗ |
| 2015-01-16 | AbbVie | Regulatory European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for the Treatment of Chronic Hepatitis C abbvie.com ↗
AbbVie (NYSE: ABBV) announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX ® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA ® (dasabuvir tablets). |
| 2014-12-19 | AbbVie | Regulatory AbbVie Receives U.S. FDA Approval of VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C abbvie.com ↗ |
| 2014-12-19 | Enanta Pharmaceuticals, Inc | Regulatory Enanta Announces U.S. Food and Drug Administration Approves AbbVie’s VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C Virus enanta.com ↗
The U.S. approval of VIEKIRA PAK triggers a $75 million regulatory approval milestone payment to Enanta from AbbVie. |
| 2014-11-21 | AbbVie | Regulatory CHMP Grants Positive Opinions of AbbVie's VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe abbvie.com ↗ |
| 2014-11-11 | AbbVie | Results AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting® 2014 abbvie.com ↗
AbbVie (NYSE: ABBV) today announced results from studies in chronic hepatitis C patients with human immunodeficiency virus type 1 (HIV-1) co-infection (TURQUOISE-I) and liver transplant recipients (CORAL-I) at The Liver Meeting®2014. |
| 2014-11-11 | AbbVie | Results AbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting® 2014 abbvie.com ↗
Additionally, 90.9 percent of patients who were new to therapy achieved SVR 12 (n=40/44) after taking the treatment without RBV. |
| 2014-09-29 | Janssen Research & Development, LLC | Regulatory CHMP Announces Positive Opinion For REZOLSTA™, A New Once-Daily, Fixed-Dose HIV Therapy Combining Darunavir And Cobicistat jnj.com ↗
The CHMP has also issued two additional label extensions relating to darunavir. |
| 2014-07-22 | Pfizer | Results ViiV Healthcare presents phase III data comparing once-daily maraviroc in combination with darunavir/ritonavir with emtricitabine/tenofovir plus darunavir/ritonavir in treatment-naïve adults with HIV-1 pfizer.com ↗
The proportion of study participants who were virologically suppressed (HIV-1 RNA <50 copies/mL) at week 48 was 77.3% for MVC+DRV/r compared to 86.8% for FTC /TDF +DRV/r (95% confidence interval -15.0% to -4.4%). |
| 2014-07-22 | GlaxoSmithKline | Results ViiV Healthcare presents phase III data gsk.com ↗
The proportion of study participants who were virologically suppressed (HIV-1 RNA <50 copies/mL) at week 48 was 77.3% for MVC+DRV/r compared to 86.8% for FTC /TDF +DRV/r (95% confidence interval -15.0% to -4.4%). |
| 2014-06-17 | AbbVie | Regulatory European Medicines Agency Validates Marketing Authorization Applications for AbbVie's Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C abbvie.com ↗
Validation of the MAAs confirms that the submissions are complete and starts the EMA's centralized review process. |
| 2014-06-13 | AbbVie | Regulatory U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C abbvie.com ↗
has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review. |
| 2014-04-22 | AbbVie | Regulatory AbbVie Submits New Drug Application to U.S. FDA for its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C abbvie.com ↗
AbbVie (NYSE: ABBV) submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. |
| 2014-04-12 | AbbVie | Results AbbVie to Present Late-Breaking Results from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis at the 2014 International Liver Congress™ abbvie.com ↗
Patients achieved sustained virologic response rates 12 weeks post-treatment (SVR 12 ) of 91.8 percent and 95.9 percent in the 12-week and 24-week treatment arms, respectively. |
| 2014-04-11 | AbbVie | Results AbbVie to Present Detailed Phase III Results from SAPPHIRE-I and SAPPHIRE-II Studies in Chronic Hepatitis C Patients at the 2014 International Liver Congress™ abbvie.com ↗
These data show very promising results in people who are infected with either subtype of the GT1 hepatitis C virus and who are either new to therapy or treatment-experienced. |
| 2014-03-05 | Merck Sharp & Dohme LLC | Results New 96-Week ACTG Study Results Presented at CROI 2014; First Large Study Comparing ISENTRESS® (raltegravir) Regimen to Two Protease Inhibitor Regimens in Previously Untreated Adults with HIV-1 merck.com ↗
On the other co-primary endpoint of failure due to tolerability, the ISENTRESS and darunavir/r regimens were superior to the atazanavir/r regimen. |
| 2014-03-05 | Bristol-Myers Squibb | Results Bristol-Myers Squibb Presents Promising Phase IIb Data for Novel, Investigational Attachment Inhibitor for HIV-1 Infected Treatment-Experienced Patients bms.com ↗
Among HIV-1 infected treatment-experienced patients receiving BMS-663068, 69-80% had HIV-1 RNA levels of < 50 c/mL (a measure indicating virus replication is undetectable), compared to 75% of patients taking Reyataz with ritonavir. |
| 2013-12-10 | AbbVie | Results AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C abbvie.com ↗
In the 394-patient SAPPHIRE-II study, 96 percent of patients who previously failed pegylated interferon and ribavirin treatment, including approximately 49 percent of who were prior null responders, achieved sustained virologic response at 12 weeks (SVR 12 ) with the regimen. |
| 2013-11-18 | AbbVie | Results AbbVie Releases First of Six Phase III Results from Investigational All-Oral, Interferon-Free, 12-week Regimen, Showing 96 Percent SVR12 in Genotype 1 Hepatitis C Patients New to Therapy abbvie.com ↗
In the 631-patient SAPPHIRE-I study, patients new to therapy receiving 12 weeks of AbbVie's 3D regimen achieved a sustained virologic response at 12 weeks post-treatment (SVR 12 ) of 96 percent. |
| 2013-09-12 | GlaxoSmithKline | Results ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naïve Adults with HIV-1 gsk.com ↗
This open-label study, for the first time, compared once-daily regimens containing 50mg dolutegravir with once-daily regimens containing a protease inhibitor (PI) (800mg darunavir boosted with 100mg ritonavir) in treatment-naïve adults with HIV-1. |
| 2013-05-06 | AbbVie | Regulatory AbbVie's Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration abbvie.com ↗
AbbVie is pleased that the FDA has granted Breakthrough Therapy designation to our 3-DAA combination with and without ribavirin. |
| 2013-04-23 | AbbVie | Results New Data from AbbVie's Phase IIb Aviator Trial Demonstrate High Sustained Viral Response Rates Across Multiple Patient Types with HCV Genotype 1 abbvie.com ↗
Data show greater than 90 percent SVR were achieved in patients new to treatment and in patients who had previously failed treatment with pegylated interferon and ribavirin (null responders). |
| 2012-07-24 | Gilead Sciences | Results Gilead’s Boosting Agent Cobicistat for HIV Therapy as Effective as Ritonavir in Pivotal Phase 3 Study gilead.com ↗
The study found that an HIV regimen containing a cobicistat-boosted protease inhibitor was non-inferior to a regimen containing a ritonavir-boosted protease inhibitor at 48 weeks of therapy. |
| 2012-07-22 | Eli Lilly and Company | Results Pharmacokinetic Study Results Released Evaluating Interactions Between LIVALO® (pitavastatin) and Protease Inhibitor Combination (darunavir/ritonavir) in Healthy Volunteers lilly.com ↗
The study, presented at the 19th International AIDS Conference in Washington, DC, found that when co-administered, the blood levels for LIVALO and each of the PIs were not significantly affected. |
| 2012-03-08 | Gilead Sciences | Results Data Show Gilead’s Quad Regimen for HIV Non-Inferior to Protease-Based Regimen at 48 Weeks in Second Pivotal Phase 3 Study gilead.com ↗
The study found that the Quad was non-inferior to a protease-based regimen of ritonavir-boosted atazanavir (ATV/r) plus Truvada ® (emtricitabine/tenofovir disoproxil fumarate) at 48 weeks of therapy among HIV-1 infected treatment-naïve adults. |
| 2012-03-06 | Merck Sharp & Dohme LLC | Results Results from Investigational Studies with VICTRELIS™ (boceprevir) Presented at the Conference on Retroviruses and Opportunistic Infections to Understand Potential Use in Patients Coinfected with Chronic Hepatitis C and HIV-1 merck.com ↗
In this study, concomitant administration of VICTRELIS with ritonavir (Norvir ® ) in combination with atazanavir (Reyataz ® ) or darunavir (Prezista ® ), or with lopinavir/ritonavir (Kaletra ® ) resulted in reduced exposures of the HIV medicines and VICTRELIS. |
| 2012-02-08 | Merck Sharp & Dohme LLC | Results Merck Informs U.S. Physicians of Results of Drug Interaction Study of Co-Administration of VICTRELIS™ with Ritonavir-Boosted HIV Protease Inhibitors merck.com ↗
In this study, concomitant administration of VICTRELIS with ritonavir (Norvir®) in combination with atazanavir (Reyataz®) or darunavir (Prezista®),or with lopinavir/ritonavir (Kaletra®) resulted in reduced exposures of the HIV medicines and VICTRELIS. |
| 2011-12-05 | Gilead Sciences | Results Gilead’s Boosting Agent, Cobicistat, Meets 48-Week Primary Objective in Pivotal Phase 3 Study gilead.com ↗
Discontinuation rates due to adverse events were 7.3 percent and 7.2 percent in the cobicistat and ritonavir arms of the study, respectively. |
| 2010-09-13 | Gilead Sciences | Results Gilead's Single-Tablet "Quad" HIV Regimen Maintains High Viral Suppression Through 48 Weeks in Phase II Study gilead.com ↗
Results from a separate study also being presented by Dr. Elion at ICAAC show that cobicistat-boosted atazanavir plus Truvada has similar efficacy and safety to ritonavir-boosted atazanavir plus Truvada at 48 weeks. |
| 2010-01-06 | Gilead Sciences | Results Phase II Clinical Trial of Gilead's Investigational Integrase-Based, Once-Daily, Fixed-Dose "Quad" Regimen Meets 24-Week Primary Objective gilead.com ↗
GS 9350-boosted atazanavir and Truvada had similar efficacy to ritonavir-boosted atazanavir and Truvada. |
| 2008-10-26 | Bristol-Myers Squibb | Results 96-Week Data From CASTLE Study Continue to Show Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/Ritonavir and Twice-Daily Lopinavir/Ritonavir In Previously Untreated HIV-1 Infected Adult Patients bms.com ↗
The CASTLE results demonstrated the non-inferiority of REYATAZ/r once daily versus lopinavir/r twice daily, each as part of HIV combination therapy in previously untreated HIV-1 infected adult patients. |
| 2008-10-01 | Bristol-Myers Squibb | Regulatory U.S. Food & Drug Administration Approved the use of REYATAZ(R) (atazanavir sulfate) Boosted with Ritonavir, in Combination Therapy, for Previously Untreated HIV-1 Infected Adult Patients bms.com ↗
Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food & Drug Administration (FDA) approved the use of REYATAZ ® (atazanavir sulfate) 300 mg once-daily boosted with ritonavir 100 mg as part of combination therapy in previously untreated (treatment-naive) HIV-1 infected patients. |
| 2008-08-05 | Bristol-Myers Squibb | Results CORRECTING and REPLACING CASTLE Data Showed Boosted REYATAZ(R) (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable Viral Load in Treatment-Naive HIV-1 Infected Patients, Regardless of Gender bms.com ↗
CASTLE DATA SHOWED BOOSTED REYATAZ ® (ATAZANAVIR SULFATE) AND LOPINAVIR/R ACHIEVED SIMILAR RESULTS FOR UNDETECTABLE VIRAL LOAD IN TREATMENT-NAIVE HIV-1 INFECTED PATIENTS, REGARDLESS OF GENDER |
| 2008-08-05 | Bristol-Myers Squibb | Results CASTLE Data Showed Boosted REYATAZ® (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable Viral Load in Treatment-Naive HIV-1 Infected Patients, Regardless of Gender bms.com ↗ |
| 2008-02-06 | Bristol-Myers Squibb | Results CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ® (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients bms.com ↗ |
| 2006-09-28 | Vertex Pharmaceuticals Incorporated | Results Vertex Pharmaceuticals and GlaxoSmithKline Announce Virologic and Drug Resistance Results from Protease Inhibitor Study vrtx.com ↗
Study results at 48 weeks showed that an HIV regimen containing LEXIVA/r administered twice-daily had comparable (non-inferior) efficacy and tolerability to lopinavir/r twice daily in treatment-naive adults. |
| 2006-08-17 | Vertex Pharmaceuticals Incorporated | Results Head-to-Head Study Comparing LEXIVA(R) (fosamprenavir calcium) to Kaletra Presented at IAC 2006 and Published in The Lancet vrtx.com ↗
The publication reported results from the KLEAN study, a randomized, open-label, multicenter, international Phase IIIb trial comparing LEXIVA/r twice-daily to lopinavir/r twice-daily in treatment-naive patients. |
| 2006-05-16 | Vertex Pharmaceuticals Incorporated | Results GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV vrtx.com ↗
Based on these results from this study, researchers have concluded that Lexiva appears to be comparable to Kaletra and has met the primary endpoints of this non-inferiority trial. |
All press releases naming this drug 109 releases
| Date | Issuer | Release |
|---|---|---|
| Show all 109 releases opens the full record — a long page | ||
Evidence & citations 29 cited values
Every value below carries the sentence it was read from. 829 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ritonavir | “This international, phase 2, open-label, multicenter study (ClinicalTrials.gov Identifier: NCT01609933) was conducted to evaluate the safety and efficacy of an enhanced regimen...” PMID 30858739 ↗ Feb 2019814“Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine,...” NCT00624195 ↗ “It may include one or two nucleoside reverse transcriptase inhibitors, such as zidovudine, didanosine, lamuvidine, zalcitabine, stavudine), a non- nucleoside reverse...” NCT00032669 ↗ “The hypothesis for this study is whether a treatment regimen containing Atazanavir in combination with Ritonavir will work as well as other regimens containing a protease...” NCT00940771 ↗ “An Open Label, Randomised, Parallel Group Study of the Drug-drug Pharmacokinetic Interaction of Steady State Tipranavir (SEDDS SEC) 500 mg and Ritonavir (Soft Gelatin Capsules)...” NCT02251873 ↗ “BACKGROUND: In this phase 3 trial we evaluated the efficacy and safety of the interferon-free combination of ABT-450 with ritonavir (ABT-450/r), ombitasvir (also known as...” PMID 24720679 ↗ Apr 2014 “Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted...” NCT01815736 ↗ “This cohort will receive ModraDoc006/r 30 mg oral docetaxel in combination with 200 mg ritonavir in the morning and 20 mg oral docetaxel in combination with 100 mg ritonavir in...” NCT04028388 ↗ “Six hundred and eighty-eight antiretroviral-naive, HIV-1-infected patients were randomized in this double-blind, placebo-matched, multicenter, noninferiority study to receive a...” PMID 19542866 ↗ Jul 2009 “One 100 mg ritonavir capsule administered twice daily at 7:00 a.m. and 7:00 p.m. on Days 15 to 18 without regard to meals, then along with colchicine at 7:00 a.m. on Day 19...” NCT00983515 ↗ “ART that concurrently contains combinations of non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, and protease-inhibitors (PIs), such as...” NCT05044962 ↗ |
| Known as | A-84538 | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | ABBOTT-84538 | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | ABT-538 | “A Pilot Study to Evaluate the Immunologic Consequences of a Highly Active Antiretroviral Therapy Regimen (HAART) Consisting of Ritonavir (ABT-538), Zidovudine (AZT), and...” NCT00001075 ↗1“A Study of Ritonavir (ABT-538) When Used With Nelfinavir in HIV-Infected Patients” NCT00002201 ↗ |
| Known as | Empetus | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | Norvir | “This study is designed to evaluate the potential for an effect of Ritonavir (Norvir®) or omeprazole (Prilosec®) on the pharmacokinetics of samatasvir and to assess the safety...” NCT01813552 ↗17“Fosamprenavir (FPV, TELZIR) is currently licensed in Europe for twice daily (BID) dosing in combination with ritonavir (RTV, Norvir) as a boosting agent” NCT00450580 ↗ “The Pharmacokinetics of SAquinavir (Invirase New Tablet Formulation) 1,000mg + Ritonavir (Norvir) 100mg q12h in HIV-infected Pregnant Women (SARA)” NCT00145561 ↗ “Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)” NCT00727597 ↗ “Norvir (ritonavir), a PI that has the ability to boost or increase the blood levels of other PIs” NCT00148785 ↗ “Lexiva (fosamprenavir calcium) 1400 mg per day, Norvir (ritonavir) 100 mg per day” NCT01010399 ↗ “Lamivudine (Epivir, GSK), Atazanavir (Reyataz, BMS), Ritonavir (Norvir, Abbott)” NCT01599364 ↗ “atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)” NCT02616783 ↗ “atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)” NCT02605954 ↗ “Ritonavir (Norvir): capsules 100 mg (1 capsule/24h)” NCT00355719 ↗ “ritonavir tablet (Norvir®): 100 mg QD.” NCT01033760 ↗ |
| Known as | Norvir (ritonavir) | “Norvir (ritonavir)” NCT01902186 ↗1“norvir (ritonavir)” NCT02265237 ↗ |
| Known as | NRV | “Ritonavir (NRV)” NCT00158405 ↗ |
| Known as | NSC-693184 | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | RIT | “the combination of the HIV protease inhibitors (HIV-PIs) saquinavir and ritonavir (SQV+RIT) in patients with idiopathic pulmonary arterial hypertension (IPAH)” PMID 26401255 ↗ Sep 2015 |
| Known as | Ritomune | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | ritonavir = Norvir trade name | “ritonavir = Norvir trade name” NCT01047995 ↗ |
| Known as | ritonavir also known as norvir | “ritonavir also known as norvir” NCT02219477 ↗3“ritonavir also known as Norvir” NCT02023099 ↗ “ritonavir also known as Norvir” NCT01672983 ↗ “Ritonavir also known as norvir” NCT02216422 ↗ |
| Known as | Ritonavir component of kaletra | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | Ritonavir component of paxlovid | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | Ritonavir component of technivie | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | Ritonavir component of viekirax | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | Ritonavir component of xiannuoxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | Ritonavir mylan | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | Ritonavir related compounds mixture | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | Ritonavirum | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | Ritovir | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | RTV | “DESIGN: ICE-001 is a phase IV, randomized, two-arm unblinded study, comparing the effect on immune reconstitution of open-label ritonavir (RTV)-enhanced lopinavir (LPV) to...” NCT00775606 ↗106“This is a Phase I, partially randomized, open-label, single-center, two-way, two-period cross-over study to investigate the pharmacokinetic interaction between etravirine (ETR)...” NCT01876966 ↗ “This study is a single-center, double-blind, randomized, placebo-controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study that will evaluate the safety,...” NCT02321384 ↗ “The purpose of this study is to see if it is safe to give saquinavir-SGC (SQV) combined with low-dose ritonavir (RTV) plus zidovudine (ZDV) and lamivudine (3TC) to HIV-positive...” NCT00000920 ↗ “In Pediatric AIDS Clinical Trials Group 377, antiretroviral therapy-experienced children were randomized to 4 treatment arms that included different combinations of stavudine,...” PMID 11372025 ↗ May 2001 “The efficacy and tolerance of switching from zidovudine (ZDV) and lamivudine (3TC) in clinically stable HIV-infected children with incomplete viral suppression to stavudine...” PMID 11840078 ↗ Feb 2002 “This 48-week randomized study examined the safety and efficacy of a switch in CART to a once-daily regimen of saquinavir (SQV), ritonavir (RTV), and atazanavir (ATV) that did...” PMID 17479946 ↗ Apr 2007 “Adult AIDS Clinical Trials Group 5043 examined pharmacokinetic (PK) interactions between amprenavir (APV) and efavirenz (EFV) both by themselves and when nelfinavir (NFV),...” PMID 16048950 ↗ Aug 2005 “Each regimen consists of 4 drugs that include a combination of nucleoside reverse transcriptase inhibitors (stavudine, lamivudine, zidovudine, didanosine, zalcitabine) plus...” NCT00000902 ↗ “This study will evaluate the predictive value of pharmacokinetic-adjusted phenotypic susceptibility (C12h/IC50) on ARV response to ritonavir (RTV)-boosted regimens in patients...” NCT00027339 ↗ “The purpose of this study is to determine whether two drugs, atazanavir (ATV) and ritonavir (RTV), will control HIV infection when taken together without any other anti-HIV...” NCT00084019 ↗ |
| Known as | Viekirax | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Known as | Viriton | ChEMBL registry synonym — accepted as the source's own label CHEMBL163 ↗ |
| Action | Inhibit | “other protease inhibitors (saquinavir/nelfinavir or saquinavir/ritonavir)” NCT00000892 ↗ |
| Modality | Other / unclassified | “Protease Inhibitor” NCT00000919 ↗ |
| Route | Oral | “A Phase I Trial of the Safety, Tolerance, and Pharmacokinetics of Oral Ritonavir Co-Administered With Lamivudine (3TC) and Zidovudine (ZDV) in HIV-1-Infected Pregnant Women and...” NCT00000888 ↗ |
| Target | CYP3A4 | “Ketoconazole and ritonavir are potent inhibitors of CYP3A4” NCT00770042 ↗ |